Table III.

hENT1 expression in samples from gemcitabine responders and non-responders.

Case	Preoperative chemotherapy	Surgical procedure	Evans classification	Adjuvant chemotherapy	Recurrence after surgery	Treatments	Date of operation
Present case	No	SSPPD	-	GEM + S-1	15 months	cCR	March 2011
Responder	GEM (6 months) + GEM + nab-PTX (6 months)	SSPPD	Grade III	S-1	24 months	Tumor shrunk with chemotherapy; after chemotherapy, conversion surgery was performed	December 2018
Non-responder case 1	GEM + S-1 (2 cycle)	SSPPD	Grade Ib	S-1	6 months	GEM + S-1, and GEM + nab-PTX performed after recurrence but no response	February 2020
Non-responder case 2	GEM + S-1 (2 cycle)	SSPPD	Grade Ia	GEM	5 months	Cancer recurred during adjuvant chemotherapy	March 2021

GEM, gemcitabine. nab-PTX, nab-paclitaxel; SSPPD, subtotal stomach-preserving pancreaticoduodenectomy. Evans classification, tumor cell destruction Grade I <10%, Grade IIa 10–50%, Grade IIb 50–90%, Grade III >90%, Grade IV no viable cells.